Ann E. Pulver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ann E. Pulver has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Gerald Nestadt
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
9 shared publications- John A. McGrath
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
9 shared publications Paula S. Wolyniec
6 shared publicationsVirginia K. Lasseter
6 shared publicationsKung-Yee Liang
5 shared publicationsDavid Valle
4 shared publications
Latest Publications
- Open Access
Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population
As part of a broader collaborative network of exome sequencing studies, we developed a jointly called data set of 5,685 Ashkenazi Jewish exomes. We make publicly available a resource of site and allele frequencies, which should serve as a reference for medical genetics in the Ashkenazim. We estimate that 30% of protein-coding alleles present in the Ashkenazi Jewish population at frequencies greater than 0.2% are significantly more frequent (mean 7.6-fold) than their maximum frequency observed in other reference populations. Arising via a well-described founder effect, this catalog of enriched alleles can contribute to differences in genetic risk and overall prevalence of diseases between populations. As validation we document 151 AJ enriched protein-altering alleles that overlap with “pathogenic” ClinVar alleles, including those that account for 10-100 fold differences in prevalence between AJ and non-AJ populations of some rare diseases including Gaucher disease ( GBA , p.Asn409Ser, 8-fold enrichment); Canavan disease ( ASPA , p.Glu285Ala, 12-fold enrichment); and Tay-Sachs disease ( HEXA , c.1421+1G>C, 27-fold enrichment; p.Tyr427IlefsTer5, 12-fold enrichment). We next sought to use this catalog, of well-established relevance to Mendelian disease, to explore Crohn’s disease, a common disease with an estimated two to four-fold excess prevalence in AJ. We specifically evaluate whether strong acting rare alleles, enriched by the same founder-effect, contribute excess genetic risk to Crohn’s disease in AJ, and find that ten rare genetic risk factors in NOD2 and LRRK2 are strongly enriched in AJ, including several novel contributing alleles, show evidence of association to CD. Independently, we find that genomewide common variant risk defined by GWAS shows a strong difference between AJ and non-AJ European control population samples (0.97 s.d. higher, p−16 ). Taken together, the results suggest coordinated selection in AJ population for higher CD risk alleles in general. The results and approach illustrate the value of exome sequencing data in case-control studies along with reference data sets like ExAC to pinpoint genetic variation that contributes to variable disease predisposition across populations.
Open AccessInsights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population
As part of a broader collaborative network of exome sequencing studies, we developed a jointly called data set of 5,685 Ashkenazi Jewish exomes. We make publicly available a resource of site and allele frequencies, which should serve as a reference for medical genetics in the Ashkenazim. We estimate that 30% of protein-coding alleles present in the Ashkenazi Jewish population at frequencies greater than 0.2% are significantly more frequent (mean 7.6-fold) than their maximum frequency observed in other reference populations. Arising via a well-described founder effect, this catalog of enriched alleles can contribute to differences in genetic risk and overall prevalence of diseases between populations. As validation we document 151 AJ enriched protein-altering alleles that overlap with “pathogenic” ClinVar alleles, including those that account for 10-100 fold differences in prevalence between AJ and non-AJ populations of some rare diseases including Gaucher disease ( GBA , p.Asn409Ser, 8-fold enrichment); Canavan disease ( ASPA , p.Glu285Ala, 12-fold enrichment); and Tay-Sachs disease ( HEXA , c.1421+1G>C, 27-fold enrichment; p.Tyr427IlefsTer5, 12-fold enrichment). We next sought to use this catalog, of well-established relevance to Mendelian disease, to explore Crohn’s disease, a common disease with an estimated two to four-fold excess prevalence in AJ. We specifically evaluate whether strong acting rare alleles, enriched by the same founder-effect, contribute excess genetic risk to Crohn’s disease in AJ, and find that ten rare genetic risk factors in NOD2 and LRRK2 are strongly enriched in AJ, including several novel contributing alleles, show evidence of association to CD. Independently, we find that genomewide common variant risk defined by GWAS shows a strong difference between AJ and non-AJ European control population samples (0.97 s.d. higher, p−16 ). Taken together, the results suggest coordinated selection in AJ population for higher CD risk alleles in general. The results and approach illustrate the value of exome sequencing data in case-control studies along with reference data sets like ExAC to pinpoint genetic variation that contributes to variable disease predisposition across populations.
- 1 December 2015
- Published by Elsevier in Schizophrenia Research
- Vol. 169 (1-3) , 121-127
Improving the understanding of the link between cognition and functional capacity in schizophrenia and bipolar disorder
- 1 December 2015
- Published by Elsevier in Schizophrenia Research
- Vol. 169 (1-3) , 121-127
Improving the understanding of the link between cognition and functional capacity in schizophrenia and bipolar disorder
- 21 July 2015
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 168 (8) , 649-659
Genome‐wide association study of schizophrenia in Ashkenazi Jews
Schizophrenia is a common, clinically heterogeneous disorder associated with lifelong morbidity and early mortality. Several genetic variants associated with schizophrenia have been identified, but the majority of the heritability remains unknown. In this study, we report on a case‐control sample of Ashkenazi Jews (AJ), a founder population that may provide additional insights into genetic etiology of schizophrenia. We performed a genome‐wide association analysis (GWAS) of 592 cases and 505 controls of AJ ancestry ascertained in the US. Subsequently, we performed a meta‐analysis with an Israeli AJ sample of 913 cases and 1640 controls, followed by a meta‐analysis and polygenic risk scoring using summary results from Psychiatric GWAS Consortium 2 schizophrenia study. The U.S. AJ sample showed strong evidence of polygenic inheritance (pseudo‐R2 ∼9.7%) and a SNP‐heritability estimate of 0.39 (P = 0.00046). We found no genome‐wide significant associations in the U.S. sample or in the combined US/Israeli AJ meta‐analysis of 1505 cases and 2145 controls. The strongest AJ specific associations (P‐values in 10−6–10−7 range) were in the 22q 11.2 deletion region and included the genes TBX1, GLN1, and COMT. Supportive evidence (meta P < 1 × 10−4) was also found for several previously identified genome‐wide significant findings, including the HLA region, CNTN4, IMMP2L, and GRIN2A. The meta‐analysis of the U.S. sample with the PGC2 results provided initial genome‐wide significant evidence for six new loci. Among the novel potential susceptibility genes is PEPD, a gene involved in proline metabolism, which is associated with a Mendelian disorder characterized by developmental delay and cognitive deficits.
- 21 July 2015
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 168 (8) , 649-659
Genome‐wide association study of schizophrenia in Ashkenazi Jews
Schizophrenia is a common, clinically heterogeneous disorder associated with lifelong morbidity and early mortality. Several genetic variants associated with schizophrenia have been identified, but the majority of the heritability remains unknown. In this study, we report on a case‐control sample of Ashkenazi Jews (AJ), a founder population that may provide additional insights into genetic etiology of schizophrenia. We performed a genome‐wide association analysis (GWAS) of 592 cases and 505 controls of AJ ancestry ascertained in the US. Subsequently, we performed a meta‐analysis with an Israeli AJ sample of 913 cases and 1640 controls, followed by a meta‐analysis and polygenic risk scoring using summary results from Psychiatric GWAS Consortium 2 schizophrenia study. The U.S. AJ sample showed strong evidence of polygenic inheritance (pseudo‐R2 ∼9.7%) and a SNP‐heritability estimate of 0.39 (P = 0.00046). We found no genome‐wide significant associations in the U.S. sample or in the combined US/Israeli AJ meta‐analysis of 1505 cases and 2145 controls. The strongest AJ specific associations (P‐values in 10−6–10−7 range) were in the 22q 11.2 deletion region and included the genes TBX1, GLN1, and COMT. Supportive evidence (meta P < 1 × 10−4) was also found for several previously identified genome‐wide significant findings, including the HLA region, CNTN4, IMMP2L, and GRIN2A. The meta‐analysis of the U.S. sample with the PGC2 results provided initial genome‐wide significant evidence for six new loci. Among the novel potential susceptibility genes is PEPD, a gene involved in proline metabolism, which is associated with a Mendelian disorder characterized by developmental delay and cognitive deficits.
- Open Access
- 31 March 2015
- Published by Springer Nature in Molecular Psychiatry
- Vol. 21 (2) , 270-276
Whole-genome association analysis of treatment response in obsessive-compulsive disorder
Up to 30% of patients with obsessive-compulsive disorder (OCD) exhibit an inadequate response to serotonin reuptake inhibitors (SRIs). To date, genetic predictors of OCD treatment response have not been systematically investigated using genome-wide association study (GWAS). To identify specific genetic variations potentially influencing SRI response, we conducted a GWAS study in 804 OCD patients with information on SRI response. SRI response was classified as ‘response’ (n=514) or ‘non-response’ (n=290), based on self-report. We used the more powerful Quasi-Likelihood Score Test (the MQLS test) to conduct a genome-wide association test correcting for relatedness, and then used an adjusted logistic model to evaluate the effect size of the variants in probands. The top single-nucleotide polymorphism (SNP) was rs17162912 (P=1.76 × 10−8), which is near the DISP1 gene on 1q41-q42, a microdeletion region implicated in neurological development. The other six SNPs showing suggestive evidence of association (P−5) were rs9303380, rs12437601, rs16988159, rs7676822, rs1911877 and rs723815. Among them, two SNPs in strong linkage disequilibrium, rs7676822 and rs1911877, located near the PCDH10 gene, gave P-values of 2.86 × 10−6 and 8.41 × 10−6, respectively. The other 35 variations with signals of potential significance (P−4) involve multiple genes expressed in the brain, including GRIN2B, PCDH10 and GPC6. Our enrichment analysis indicated suggestive roles of genes in the glutamatergic neurotransmission system (false discovery rate (FDR)=0.0097) and the serotonergic system (FDR=0.0213). Although the results presented may provide new insights into genetic mechanisms underlying treatment response in OCD, studies with larger sample sizes and detailed information on drug dosage and treatment duration are needed.
- 31 March 2015
- Published by Springer Nature in Molecular Psychiatry
- Vol. 21 (2) , 270-276
Open AccessWhole-genome association analysis of treatment response in obsessive-compulsive disorder
Up to 30% of patients with obsessive-compulsive disorder (OCD) exhibit an inadequate response to serotonin reuptake inhibitors (SRIs). To date, genetic predictors of OCD treatment response have not been systematically investigated using genome-wide association study (GWAS). To identify specific genetic variations potentially influencing SRI response, we conducted a GWAS study in 804 OCD patients with information on SRI response. SRI response was classified as ‘response’ (n=514) or ‘non-response’ (n=290), based on self-report. We used the more powerful Quasi-Likelihood Score Test (the MQLS test) to conduct a genome-wide association test correcting for relatedness, and then used an adjusted logistic model to evaluate the effect size of the variants in probands. The top single-nucleotide polymorphism (SNP) was rs17162912 (P=1.76 × 10−8), which is near the DISP1 gene on 1q41-q42, a microdeletion region implicated in neurological development. The other six SNPs showing suggestive evidence of association (P−5) were rs9303380, rs12437601, rs16988159, rs7676822, rs1911877 and rs723815. Among them, two SNPs in strong linkage disequilibrium, rs7676822 and rs1911877, located near the PCDH10 gene, gave P-values of 2.86 × 10−6 and 8.41 × 10−6, respectively. The other 35 variations with signals of potential significance (P−4) involve multiple genes expressed in the brain, including GRIN2B, PCDH10 and GPC6. Our enrichment analysis indicated suggestive roles of genes in the glutamatergic neurotransmission system (false discovery rate (FDR)=0.0097) and the serotonergic system (FDR=0.0213). Although the results presented may provide new insights into genetic mechanisms underlying treatment response in OCD, studies with larger sample sizes and detailed information on drug dosage and treatment duration are needed.
- Open Access
- 17 March 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0116696
Infection and Inflammation in Schizophrenia and Bipolar Disorder: A Genome Wide Study for Interactions with Genetic Variation
Inflammation and maternal or fetal infections have been suggested as risk factors for schizophrenia (SZ) and bipolar disorder (BP). It is likely that such environmental effects are contingent on genetic background. Here, in a genome-wide approach, we test the hypothesis that such exposures increase the risk for SZ and BP and that the increase is dependent on genetic variants. We use genome-wide genotype data, plasma IgG antibody measurements against Toxoplasma gondii, Herpes simplex virus type 1, Cytomegalovirus, Human Herpes Virus 6 and the food antigen gliadin as well as measurements of C-reactive protein (CRP), a peripheral marker of inflammation. The subjects are SZ cases, BP cases, parents of cases and screened controls. We look for higher levels of our immunity/infection variables and interactions between them and common genetic variation genome-wide. We find many of the antibody measurements higher in both disorders. While individual tests do not withstand correction for multiple comparisons, the number of nominally significant tests and the comparisons showing the expected direction are in significant excess (permutation p=0.019 and 0.004 respectively). We also find CRP levels highly elevated in SZ, BP and the mothers of BP cases, in agreement with existing literature, but possibly confounded by our inability to correct for smoking or body mass index. In our genome-wide interaction analysis no signal reached genome-wide significance, yet many plausible candidate genes emerged. In a hypothesis driven test, we found multiple interactions among SZ-associated SNPs in the HLA region on chromosome 6 and replicated an interaction between CMV infection and genotypes near the CTNNA3 gene reported by a recent GWAS. Our results support that inflammatory processes and infection may modify the risk for psychosis and suggest that the genotype at SZ-associated HLA loci modifies the effect of these variables on the risk to develop SZ.
- 17 March 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0116696
Open AccessInfection and Inflammation in Schizophrenia and Bipolar Disorder: A Genome Wide Study for Interactions with Genetic Variation
Inflammation and maternal or fetal infections have been suggested as risk factors for schizophrenia (SZ) and bipolar disorder (BP). It is likely that such environmental effects are contingent on genetic background. Here, in a genome-wide approach, we test the hypothesis that such exposures increase the risk for SZ and BP and that the increase is dependent on genetic variants. We use genome-wide genotype data, plasma IgG antibody measurements against Toxoplasma gondii, Herpes simplex virus type 1, Cytomegalovirus, Human Herpes Virus 6 and the food antigen gliadin as well as measurements of C-reactive protein (CRP), a peripheral marker of inflammation. The subjects are SZ cases, BP cases, parents of cases and screened controls. We look for higher levels of our immunity/infection variables and interactions between them and common genetic variation genome-wide. We find many of the antibody measurements higher in both disorders. While individual tests do not withstand correction for multiple comparisons, the number of nominally significant tests and the comparisons showing the expected direction are in significant excess (permutation p=0.019 and 0.004 respectively). We also find CRP levels highly elevated in SZ, BP and the mothers of BP cases, in agreement with existing literature, but possibly confounded by our inability to correct for smoking or body mass index. In our genome-wide interaction analysis no signal reached genome-wide significance, yet many plausible candidate genes emerged. In a hypothesis driven test, we found multiple interactions among SZ-associated SNPs in the HLA region on chromosome 6 and replicated an interaction between CMV infection and genotypes near the CTNNA3 gene reported by a recent GWAS. Our results support that inflammatory processes and infection may modify the risk for psychosis and suggest that the genotype at SZ-associated HLA loci modifies the effect of these variables on the risk to develop SZ.
- Open Access
- 1 June 2009
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 66 (6) , 591-600
Familiality of Novel Factorial Dimensions of Schizophrenia
Schizophrenia (SZ) is a disabling complex disease with a prevalence of about 1%,1 typically arising in late adolescence or early adulthood. Symptoms, which include delusions, paranoia, anhedonia, hallucinations, lack of motivation, and cognitive and affective disturbances, can vary substantially between patients and over time. The etiology of SZ remains unknown; however, twin, adoption, and family studies suggest genetic involvement with heritability estimated to be as high as 70% to 85%.2,3 It has been suggested that 3 or 4 loci with likely epistatic interactions might be involved in SZ susceptibility.4 Linkage studies have implicated more than a dozen chromosomal regions5; however, various meta-analytic methods have not substantially reduced this number.6,7 Genomewide significance has been demonstrated only for regions on chromosomes 13q8 and 1q.9 Association studies have followed linkage studies or investigated functional candidate genes,10,11 with some promising results; however, findings have not been conclusively replicated.12
- 1 June 2009
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 66 (6) , 591-600
Open AccessFamiliality of Novel Factorial Dimensions of Schizophrenia
Schizophrenia (SZ) is a disabling complex disease with a prevalence of about 1%,1 typically arising in late adolescence or early adulthood. Symptoms, which include delusions, paranoia, anhedonia, hallucinations, lack of motivation, and cognitive and affective disturbances, can vary substantially between patients and over time. The etiology of SZ remains unknown; however, twin, adoption, and family studies suggest genetic involvement with heritability estimated to be as high as 70% to 85%.2,3 It has been suggested that 3 or 4 loci with likely epistatic interactions might be involved in SZ susceptibility.4 Linkage studies have implicated more than a dozen chromosomal regions5; however, various meta-analytic methods have not substantially reduced this number.6,7 Genomewide significance has been demonstrated only for regions on chromosomes 13q8 and 1q.9 Association studies have followed linkage studies or investigated functional candidate genes,10,11 with some promising results; however, findings have not been conclusively replicated.12
- 1 December 2005
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 77 (6) , 918-936
Bipolar I Disorder and Schizophrenia: A 440–Single-Nucleotide Polymorphism Screen of 64 Candidate Genes among Ashkenazi Jewish Case-Parent Trios
- 1 December 2005
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 77 (6) , 918-936
Bipolar I Disorder and Schizophrenia: A 440–Single-Nucleotide Polymorphism Screen of 64 Candidate Genes among Ashkenazi Jewish Case-Parent Trios
- 1 August 2004
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 75 (2) , 204-219
Genomewide Linkage Scan for Bipolar-Disorder Susceptibility Loci among Ashkenazi Jewish Families
- 1 August 2004
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 75 (2) , 204-219
Genomewide Linkage Scan for Bipolar-Disorder Susceptibility Loci among Ashkenazi Jewish Families
- Open Access
- 1 January 2004
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 30 (4) , 855-873
Five Latent Factors Underlying Schizophrenia: Analysis and Relationship to Illnesses in Relatives
Clinical signs and symptoms in a sample of 1,043 individuals with schizophrenia or schizoaffective disorder were subjected to latent class factor analysis. Positive, negative, disorganized, and affective factors were similar in content to factors described in a number of other studies, while a fifth factor representing early onset/developmental signs provided a new area for investigation. The five sets of factor scores were logistically regressed on psychiatric illness indicators in first and second degree relatives. Relatives of probands with higher positive or negative symptom factor scores had a lower risk of depressive illness. Higher affective factor scores in probands predicted more mania and depression in relatives. Both the disorganized and the early onset/developmental factors were related to increased risk of psychiatric hospitalization in relatives, as well as increased risk of psychosis (marginally so for the disorganization factor). Increased early onset/developmental signs in the proband were also associated with increased risk for depression in relatives. These findings suggest a possible endophenotypic role for the factor scores in future studies.
- 1 January 2004
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 30 (4) , 855-873
Open AccessFive Latent Factors Underlying Schizophrenia: Analysis and Relationship to Illnesses in Relatives
Clinical signs and symptoms in a sample of 1,043 individuals with schizophrenia or schizoaffective disorder were subjected to latent class factor analysis. Positive, negative, disorganized, and affective factors were similar in content to factors described in a number of other studies, while a fifth factor representing early onset/developmental signs provided a new area for investigation. The five sets of factor scores were logistically regressed on psychiatric illness indicators in first and second degree relatives. Relatives of probands with higher positive or negative symptom factor scores had a lower risk of depressive illness. Higher affective factor scores in probands predicted more mania and depression in relatives. Both the disorganized and the early onset/developmental factors were related to increased risk of psychiatric hospitalization in relatives, as well as increased risk of psychosis (marginally so for the disorganization factor). Increased early onset/developmental signs in the proband were also associated with increased risk for depression in relatives. These findings suggest a possible endophenotypic role for the factor scores in future studies.
- 1 September 2003
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 73 (3) , 601-611
Genomewide Linkage Scan for Schizophrenia Susceptibility Loci among Ashkenazi Jewish Families Shows Evidence of Linkage on Chromosome 10q22
- 1 September 2003
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 73 (3) , 601-611
Genomewide Linkage Scan for Schizophrenia Susceptibility Loci among Ashkenazi Jewish Families Shows Evidence of Linkage on Chromosome 10q22